HepatologyPub Date : 2026-11-12DOI: 10.1097/hep.0000000000001915
Hiroaki Kanzaki, Yujin Hoshida, Young Nyun Park
{"title":"Digital pathology in hepatocellular carcinoma: From prognostic prediction to biological understanding and precision medicine","authors":"Hiroaki Kanzaki, Yujin Hoshida, Young Nyun Park","doi":"10.1097/hep.0000000000001915","DOIUrl":"https://doi.org/10.1097/hep.0000000000001915","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"5 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HepatologyPub Date : 2026-11-10DOI: 10.1097/hep.0000000000001911
Alberto Calleri, Yihong Deng, Kamalpreet S. Hara, Gabriel Prusch Fernandes, Katherine M. Williams, Sara M. Kloft-Nelson, Angela M. Leuenberger, Mindy M. Mickelson, Lindsey R. Sangaralingham, Puru Rattan, Patrick S. Kamath, Vijay H. Shah, Daniel Penrice, Douglas A. Simonetto
{"title":"Remote patient management reduces liver-related hospitalizations in patients with acutely decompensated cirrhosis","authors":"Alberto Calleri, Yihong Deng, Kamalpreet S. Hara, Gabriel Prusch Fernandes, Katherine M. Williams, Sara M. Kloft-Nelson, Angela M. Leuenberger, Mindy M. Mickelson, Lindsey R. Sangaralingham, Puru Rattan, Patrick S. Kamath, Vijay H. Shah, Daniel Penrice, Douglas A. Simonetto","doi":"10.1097/hep.0000000000001911","DOIUrl":"https://doi.org/10.1097/hep.0000000000001911","url":null,"abstract":"Background: Patients with decompensated cirrhosis experience frequent hospitalizations, yet evidence supporting remote post-discharge care remains limited. This study assessed the impact of cirrhosis-specific Remote Patient Management (CiRPM) program following hospitalization for acutely decompensated (AD) cirrhosis. Methods: Adults hospitalized for AD cirrhosis were included in a three-cohort observational study comparing CiRPM (2021-2024) with contemporary (C-control) and historical controls (H-control, 2018-2019). CiRPM enabled vital-sign and symptom transmission with 24/7 virtual nursing support. Subgroup analyses were conducted by disease etiology, CLIF-C AD score, and decompensation type. IPTW was used to adjust for confounding, and time-to-event outcomes were analyzed using Cox proportional hazards models. Results: Among 430 patients (156 CiRPM, 152 H-control, 122 C-control), mean age was 59 years, 65% had alcohol-associated liver disease (ALD), CLIF-C AD score of 56. CiRPM was associated with lower 90-day liver-related readmissions versus C-control (39% vs. 58%; HR 0.57, <jats:italic toggle=\"yes\">p</jats:italic> =0.01) and a similar trend versus H-control (39% vs. 52%; HR 0.67, <jats:italic toggle=\"yes\">p</jats:italic> =0.07). Associations were stronger among patients with CLIF-C AD ≥60 (HR 0.43 vs. H-control, <jats:italic toggle=\"yes\">p</jats:italic> =0.005; HR 0.51 vs. C-control, <jats:italic toggle=\"yes\">p</jats:italic> =0.02). Among ALD patients, fewer fluid-related readmissions (OR 0.40 and 0.37; both <jats:italic toggle=\"yes\">p</jats:italic> <0.001) and recurrent hospitalizations (OR 0.51; <jats:italic toggle=\"yes\">p</jats:italic> =0.001 and <jats:italic toggle=\"yes\">p</jats:italic> =0.002) were observed in the CiRPM group. In non-ALD patients, hepatic encephalopathy readmissions were lower (OR 0.29, <jats:italic toggle=\"yes\">p</jats:italic> =0.004; OR 0.36, <jats:italic toggle=\"yes\">p</jats:italic> =0.02). Mortality did not differ across groups. Conclusion: CiRPM enrollment was associated with fewer liver-related hospitalizations, particularly among patients with ALD and CLIF-C AD ≥60, supporting targeted remote management as a scalable post-discharge strategy for this high-risk population.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"16 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HepatologyPub Date : 2026-11-06DOI: 10.1097/HEP.0000000000001909
Joseph K Lim, Jose D Debes, Jordan J Feld, Ramazan Idilman, Norah A Terrault
{"title":"AASLD EXPO: Diagnosis and management of hepatitis delta virus (HDV) infection.","authors":"Joseph K Lim, Jose D Debes, Jordan J Feld, Ramazan Idilman, Norah A Terrault","doi":"10.1097/HEP.0000000000001909","DOIUrl":"https://doi.org/10.1097/HEP.0000000000001909","url":null,"abstract":"<p><strong>Background: </strong>HDV infection represents a rare co-infection or super-infection among persons with HBV infection and is associated with significant morbidity and mortality due to an increased risk of liver events such as hepatic decompensation and HCC.</p><p><strong>Methods: </strong>The Expert Practice Opinion (EXPO) document was developed by subject matter experts and commissioned by the AASLD Practice Guidelines Committee to provide timely guidance on the screening, diagnosis, and management of HDV infection. Writing group members performed a targeted literature review and generated EXPO statements which were agreed upon by group consensus.</p><p><strong>Results: </strong>All individuals who are HBsAg positive should be tested at least once for HDV infection with HDV antibody. HDV antibody positive individuals should undergo HDV RNA testing to confirm active infection. All individuals with chronic HDV should undergo further evaluation including non-invasive fibrosis testing, preferably with elastography. Lab monitoring and HCC surveillance imaging is suggested every 6 months. All adults with chronic HDV viremia and compensated liver disease should be considered candidates for HDV therapy with bulevirtide for chronic virologic suppression, or alternatively bulevirtide plus peg-IFN alfa-2a for individuals without contraindications to peg-IFN and who desire a finite duration regimen. Considerations for patient selection, treatment regimen, monitoring, assessment of response, and care of patients in special populations are summarized in the document.</p><p><strong>Conclusions: </strong>All HBsAg positive individuals should be screened for HDV. All adults with chronic HDV and compensated liver disease are candidates for HDV therapy. Recent advances in HDV treatment offer hope for meaningful improvement in clinical outcomes.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HepatologyPub Date : 2026-11-05DOI: 10.1097/HEP.0000000000001838
John P Rice, Kimberly Brown, Meena B Bansal
{"title":"Introducing Michael Ronan Lucey, MD, the 78th President of AASLD.","authors":"John P Rice, Kimberly Brown, Meena B Bansal","doi":"10.1097/HEP.0000000000001838","DOIUrl":"https://doi.org/10.1097/HEP.0000000000001838","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HepatologyPub Date : 2026-11-05DOI: 10.1097/HEP.0000000000001906
Kris V Kowdley, Eric Lawitz, Christopher L Bowlus, Kuldeep Cheent, Matthieu Guivarch, Vaclav Hejda, Jeong Heo, Byoung K Jang, Wonseok Kang, Carmen Landaverde, Anna S Lok, Ashis Mukhopadhya, Antonio Olveira, Bhaktasharan Patel, Fabian Rodas Ochoa, Sergio Rodríguez-Tajes, Jan Sperl, Frank E Uschner, Ziad Younes, Gillian Bubb, Valeria Cranham, George Harb, Claire Raskino, Philip J F Troke, Benjamin Miller, Ana Lleo
{"title":"Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial.","authors":"Kris V Kowdley, Eric Lawitz, Christopher L Bowlus, Kuldeep Cheent, Matthieu Guivarch, Vaclav Hejda, Jeong Heo, Byoung K Jang, Wonseok Kang, Carmen Landaverde, Anna S Lok, Ashis Mukhopadhya, Antonio Olveira, Bhaktasharan Patel, Fabian Rodas Ochoa, Sergio Rodríguez-Tajes, Jan Sperl, Frank E Uschner, Ziad Younes, Gillian Bubb, Valeria Cranham, George Harb, Claire Raskino, Philip J F Troke, Benjamin Miller, Ana Lleo","doi":"10.1097/HEP.0000000000001906","DOIUrl":"https://doi.org/10.1097/HEP.0000000000001906","url":null,"abstract":"<p><strong>Background aims: </strong>Definitions of primary biliary cholangitis (PBC) treatment response commonly include alkaline phosphatase (ALP) <1.67× upper limit of normal (ULN). However, ALP >ULN is associated with active disease and reduced transplant-free survival, whereas ALP normalization is associated with better complication-free survival. Elafibranor, a peroxisome proliferator-activated receptor (PPAR)-α/δ agonist, has been shown to be effective and well-tolerated as a second-line treatment in patients with PBC and ALP ≥1.67x ULN. We report phase III ELSPIRE trial results, evaluating the effect of one year of elafibranor treatment on ALP normalization (ALP ≤ULN; ≤120 U/L) in patients with PBC and ALP >1-<1.67× ULN after incomplete response/intolerance to ursodeoxycholic acid.</p><p><strong>Approach results: </strong>In ELSPIRE, 92 patients were randomized, double-blind, 2:1 to elafibranor 80 mg (n=62) or placebo (n=30) for 52 weeks, stratified by ALP at randomization (>1-≤1.33× ULN vs. >1.33-<1.67× ULN). At Week 52, 85.3% of patients receiving elafibranor achieved the primary endpoint of ALP normalization, versus 23.3% receiving placebo (treatment difference: 62.0%; 95% CI: 44.3, 79.7; p<0.0001). Least squares mean percentage change from baseline in ALP at Week 52 was -36.5% with elafibranor versus -4.2% with placebo (p<0.0001). A greater proportion of patients receiving elafibranor versus placebo achieved ALP normalization with ≥15% reduction from baseline and complete biochemical response (normal ALP, total bilirubin, transaminases, albumin, and INR). Elafibranor was well tolerated; no new safety signals were observed.</p><p><strong>Conclusions: </strong>These results support elafibranor as second-line treatment with UDCA for patients with PBC and ALP >1-<1.67× ULN, with ALP normalization as an achievable treatment goal.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HepatologyPub Date : 2026-11-05DOI: 10.1097/HEP.0000000000001912
Wanzhu Tu, Jun Li, Michael Charlton, Naga Chalasani, Laura E Nagy
{"title":"ATTEST 2027: A Framework for AI Transparency Tiered by Evidentiary Stakes.","authors":"Wanzhu Tu, Jun Li, Michael Charlton, Naga Chalasani, Laura E Nagy","doi":"10.1097/HEP.0000000000001912","DOIUrl":"https://doi.org/10.1097/HEP.0000000000001912","url":null,"abstract":"<p><p>Artificial intelligence (AI) is now being used across scientific research workflows, from data extraction and code generation to literature synthesis and manuscript drafting. Scientific journals and professional organizations agree that authors should disclose AI assistance. But disclosure that treats all AI use equally with a single generic declaration reveals little about the nature of AI's influence on evidence generation. Polishing grammar carries a different risk than extracting outcomes from clinical notes, classifying pathology, or making causal inference. We propose ATTEST (AI Transparency Tiered by Evidentiary Stakes), a framework that evaluates AI assistance by its consequences. ATTEST classifies AI use into eight broad categories of functions, each scored at one of four risk tiers (Low, Medium, High, Very High). The framework is operationalized by a declaration checklist that authors complete at submission. Within this tiered system, we propose minimum reporting standards by function, cross-cutting requirements, and obligations for reviewers and editors. The goal is to make AI's role in evidence generation transparent to readers, reviewers, and editors so they can evaluate the integrity of scientific findings.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HepatologyPub Date : 2026-11-05DOI: 10.1097/HEP.0000000000001903
Raj Vuppalanchi, Marco Carbone
{"title":"Elafibranor for primary biliary cholangitis at ALP below 1.67 × ULN: Progress toward a goal, no evidence yet of arrival.","authors":"Raj Vuppalanchi, Marco Carbone","doi":"10.1097/HEP.0000000000001903","DOIUrl":"https://doi.org/10.1097/HEP.0000000000001903","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HepatologyPub Date : 2026-11-02DOI: 10.1097/HEP.0000000000001908
Maria Mironova, Bachir Taouli, Richard L Ehman, Claude B Sirlin, Rohit Loomba
{"title":"MRI-based biomarkers for risk stratification and assessment of treatment response in Metabolic dysfunction-associated Steatotic liver disease.","authors":"Maria Mironova, Bachir Taouli, Richard L Ehman, Claude B Sirlin, Rohit Loomba","doi":"10.1097/HEP.0000000000001908","DOIUrl":"https://doi.org/10.1097/HEP.0000000000001908","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to 38% of the population globally. Liver biopsy, the historical reference standard, is invasive, subject to sampling error and not scalable. MRI-based biomarkers provide non-invasive, quantitative whole liver assessment. MRI proton density fat fraction (MRI-PDFF) is the most accurate noninvasive measure of steatosis (thresholds of 6.4%, 17.4% and 22.1% for grades ≥1, ≥2 and 3), and a ≥30% relative reduction is associated with histologic response. Liver stiffness by magnetic resonance elastography (MRE-LS) is the most accurate imaging biomarker for fibrosis: MRE-LS of 3.1-4.4 kPa corresponds to F2-F3 and ≥5 kPa to cirrhosis, and each 1-kPa increase is associated with a 43% higher risk of hepatic decompensation. Iron-corrected T1 is a sensitive but nonspecific marker of disease activity whose prognostic value requires further study. Composite scores, MAST, MEFIB, and MASH Resolution Index, combine imaging and blood tests for advanced fibrosis diagnosis and response assessment. MRE is cost-effective compared with vibration-controlled transient elastography for detecting advanced fibrosis. Artificial intelligence may broaden access by automating analysis and enabling PDFF from routine MRI. We review the evidence supporting these biomarkers for diagnosis, prognosis and regulatory use, and their role in clinical trials and in treatment decisions for approved MASH therapies.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":18.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease.","authors":"Shaoyang Qin, Xiaochen Bo, Hongyuan Liu, Zhishuo Zhang, Zhicong Zhao, Qiang Xia","doi":"10.1097/HEP.0000000000001321","DOIUrl":"10.1097/HEP.0000000000001321","url":null,"abstract":"<p><p>End-stage liver disease represents a critical hepatic condition with high mortality, for which liver transplantation remains the only effective treatment. However, the scarcity of suitable donors results in numerous patients dying while awaiting transplantation. Novel strategies, including cell therapies and technologies mimicking liver organogenesis, offer promising alternatives for treating end-stage liver disease by potentially providing new sources of liver grafts. Recently, significant progress has been made in this field, including stem cell transplantation, hepatocyte transplantation, in vitro liver tissue generation, and liver replacement technologies. Several clinical studies have demonstrated that stem cell transplantation and hepatocyte transplantation can prolong patient survival and serve as a bridge to liver transplantation. Furthermore, in vitro liver tissue generation technologies, such as liver organoids and three-dimensional bioprinting, can generate hepatic tissues with sophisticated structures and functions, making them promising transplantation materials. Notably, liver replacement technologies hold considerable potential for producing biologically functional and transplantable liver grafts. In this review, we discuss the fundamental principles and recent advancements in cell therapies and liver organogenesis technologies while also addressing the challenges and future prospects in this rapidly evolving field.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"1567-1586"},"PeriodicalIF":18.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143770815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}